Table 5.
Haplotype Frequencies of MSR1 Sequence Variants in Patients with Prostate Cancer and Unaffected Control Subjects
|
Frequency (95% CI) |
P values (empirical) |
||
| Haplotypea | Control Subjects | Case Subjects | Haplotype Specific |
| A (−) C C (−) | 83.6% (80.3–86.9) | 81.8% (78.7–84.9) | .44 |
| G (+) A C (−) | 2.6% (1.2–4.0) | 6.6% (4.6–8.6) | .004 |
| A (−) C G (+) | 6.5% (4.3–8.6) | 4.0% (2.4–5.5) | .06 |
| G (+) C C (−) | 3.7% (2.1–5.4) | 4.1% (2.5–5.7) | .77 |
| Global | .011 | ||
a
Haplotype of five SNPs (in the order of PRO3, INDEL1, IVS-59, P275A, and INDEL7)